BioLife Solutions Inc
NASDAQ:BLFS

Watchlist Manager
BioLife Solutions Inc Logo
BioLife Solutions Inc
NASDAQ:BLFS
Watchlist
Price: 27.39 USD 4.9% Market Closed
Market Cap: 1.3B USD
Have any thoughts about
BioLife Solutions Inc?
Write Note

BioLife Solutions Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BioLife Solutions Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
BioLife Solutions Inc
NASDAQ:BLFS
Total Current Liabilities
$32.2m
CAGR 3-Years
-4%
CAGR 5-Years
46%
CAGR 10-Years
45%
Haemonetics Corp
NYSE:HAE
Total Current Liabilities
$273.9m
CAGR 3-Years
-2%
CAGR 5-Years
3%
CAGR 10-Years
5%
ICU Medical Inc
NASDAQ:ICUI
Total Current Liabilities
$549.6m
CAGR 3-Years
44%
CAGR 5-Years
17%
CAGR 10-Years
34%
Align Technology Inc
NASDAQ:ALGN
Total Current Liabilities
$2.1B
CAGR 3-Years
5%
CAGR 5-Years
19%
CAGR 10-Years
26%
Lantheus Holdings Inc
NASDAQ:LNTH
Total Current Liabilities
$784.1m
CAGR 3-Years
117%
CAGR 5-Years
67%
CAGR 10-Years
29%
Merit Medical Systems Inc
NASDAQ:MMSI
Total Current Liabilities
$201.1m
CAGR 3-Years
-2%
CAGR 5-Years
6%
CAGR 10-Years
10%
No Stocks Found

BioLife Solutions Inc
Glance View

Market Cap
1.3B USD
Industry
Health Care

BioLife Solutions Inc., hailing from Bothell, Washington, tells a story of innovation within the niche yet critical biopreservation industry. Emerging as a vital player for cell and gene therapy developers, BioLife Solutions specializes in creating hypothermic storage and transport media tailored for fragile biologic material. Their cornerstone products, like CryoStor and HypoThermosol, are formulated to prolong the shelf-life and viability of cells, tissues, and organs during storage and transportation. These solutions are designed for ultra-cold environments, ensuring the cellular integrity required by biopharmaceutical companies and research institutions engaged in the leading-edge development of regenerative medicine. The company's business model is centered around both direct sales and strategic partnerships. By deeply embedding its proprietary preservation media into clinical-grade processes, BioLife Solutions establishes itself as an integral component of its clients' supply chains. In doing so, the company generates revenue not just from initial sales of its products, but from ongoing usage as therapies move through development pipelines into mainstream clinical applications. Additionally, their diversification into automated thawing devices and personalized medicine services bolster recurring revenue streams, positioning them strategically in an expanding market driven by technological advancements in cellular therapies. Thus, BioLife Solutions stands firmly at the confluence of innovation and necessity, drawing strength from its strategic foresight and commitment to preserving the future of medicine.

BLFS Intrinsic Value
6.98 USD
Overvaluation 75%
Intrinsic Value
Price

See Also

What is BioLife Solutions Inc's Total Current Liabilities?
Total Current Liabilities
32.2m USD

Based on the financial report for Sep 30, 2024, BioLife Solutions Inc's Total Current Liabilities amounts to 32.2m USD.

What is BioLife Solutions Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
45%

Over the last year, the Total Current Liabilities growth was -24%. The average annual Total Current Liabilities growth rates for BioLife Solutions Inc have been -4% over the past three years , 46% over the past five years , and 45% over the past ten years .

Back to Top